EpistemisAdvanced Clinical Support: Febrile Neutropenia and Tumor Lysis Syndrome
Systematic analytical monitoring of complications derived from massive cell lysis or damage to the hematopoietic barrier is a critical part of cancer patient care. Febrile neutropenia and tumor lysis syndromes represent emergencies that require immediate diagnostic and therapeutic intervention.
File
Febrile Neutropenia: Diagnosis, Classification of MASCC and Antibiotic Therapy
It is defined clinically by the presence of a single oral temperature measurement > 38.3 °C or > 38.0 °C maintained for more than 1 hour, combined with an Absolute Neutrophil Count (ANC) < 500/mm³ (or expected to decline below that threshold in the following 48 hours):
ANC = Total leukocytes (/mm3) × (% Sec Neutrophils + % Cages)/(100)
1. MASCC Risk Classification: Score 21 classifies the patient as low risk (suitable for outpatient oral management); score < 21 classifies as high risk (requires mandatory emergency hospital admission).
2. First-Line Treatment in High Risk: Initiate as a priority in the first hour of admission, after rapid collection of paired blood cultures, broad-spectrum empirical intravenous antibiotic therapy with active antipseudomonal activity: Piperacillin-Tazobactam (4.5 g IV every 6 hours) or Cefepime or Meropenem.
3. Prophylaxis with Stimulating Factors: In regimens with a risk of febrile neutropenia > 20%, Filgrastim (G-CSF) is prescribed at a dose of 5 µ g/kg/day subcutaneously daily starting the day after chemotherapy, or a single dose of Pegfilgrastim (6 mg SC).
Tumor Lysis Syndrome (TLS): Cairo-Bishop Criteria and Support
It occurs secondary to rapid tumor cell destruction after high-potency chemotherapy in high-burden lymphomas or acute leukemias, with massive release of intracellular electrolytes and nuclear debris into the circulation:
Tumor Lysis ↑ Uric Acid, ↑ Potassium, ↑ Phosphorus and ↓ Calcium
- Cairo-Bishop Criteria for Analytical SLT: Presence of at least two of the following changes within 3-7 days of starting chemotherapy: Uric acid 8 mg/dL, Potassium 6 mEq/L, Phosphorus 4.5 mg/dL or Calcium 7 mg/dL.
- Supportive Management: Aggressive hyperhydrated intravenous hydration to maintain diuresis of 100 mL/m2/hour with strict analytical control.
- Use of Rasburicase: Recombinant urate oxidase that transforms insoluble uric acid into soluble allantoin, clearing kidney overload. Dosed at 0.15 - 0.2 mg/kg IV once daily as a 30-minute infusion in cases of established TLS. Absolutely contraindicated in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency due to the risk of severe hemolysis and methemoglobinemia.
Epistemis is educational review material. It is not a medical device, does not diagnose or prescribe treatment, and does not replace formal medical training, current clinical guidelines, or professional clinical judgment.
- System
- Oncology
- Cluster
- Treatment of Oncological Complications and Emergencies